These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 20585746)

  • 41. Adverse Reactions to Biologics in Psoriasis.
    Lockwood SJ; Prens LM; Kimball AB
    Curr Probl Dermatol; 2018; 53():1-14. PubMed ID: 29131033
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review.
    Maliyar K; Crowley EL; Rodriguez-Bolanos F; O'Toole A; Gooderham MJ
    J Cutan Med Surg; 2019; 23(4):428-435. PubMed ID: 30938189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis.
    Siegel SAR; Winthrop KL
    Curr Rheumatol Rep; 2019 Jun; 21(7):36. PubMed ID: 31172303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Infliximab: patients selection].
    Puig L
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():23-9. PubMed ID: 19080988
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Response of severe psoriasis to infliximab.
    Mang R; Stege H; Ruzicka T; Krutmann J
    Dermatology; 2002; 204(2):156-7. PubMed ID: 11937748
    [No Abstract]   [Full Text] [Related]  

  • 46. Depression and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists.
    Wu CY; Chang YT; Juan CK; Shen JL; Lin YP; Shieh JJ; Liu HN; Chen YJ
    Medicine (Baltimore); 2016 May; 95(22):e3816. PubMed ID: 27258525
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Secukinumab (AIN-457) for the treatment of Psoriasis.
    Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
    Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis.
    Fantuzzi F; Del Giglio M; Gisondi P; Girolomoni G
    Expert Opin Ther Targets; 2008 Sep; 12(9):1085-96. PubMed ID: 18694376
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current therapeutic approaches of psoriasis are affected by age at disease onset.
    Di Lernia V; Ficarelli E
    J Dermatolog Treat; 2014 Feb; 25(1):15-7. PubMed ID: 23210896
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
    Ten Bergen LL; Petrovic A; Krogh Aarebrot A; Appel S
    Scand J Immunol; 2020 Oct; 92(4):e12946. PubMed ID: 32697374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.
    van de Kerkhof PC; Reich K; Kavanaugh A; Bachelez H; Barker J; Girolomoni G; Langley RG; Paul CF; Puig L; Lebwohl MG
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2002-10. PubMed ID: 25885420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort.
    Ruiz-Genao D; Perez-Zafrilla B; Lopez-Estebaranz JL; Belinchón-Romero I; Carrascosa JM; Ferrán M; Vanaclocha F; Herrera-Ceballos E; García-Doval I;
    Br J Dermatol; 2017 Mar; 176(3):797-799. PubMed ID: 27120993
    [No Abstract]   [Full Text] [Related]  

  • 53. [Body-weight changes in psoriatic patients on systemic treatment].
    Forien M; Mahé E; Sin C; Marchal A; Sigal ML
    Ann Dermatol Venereol; 2012 Oct; 139(10):649-51. PubMed ID: 23122380
    [No Abstract]   [Full Text] [Related]  

  • 54. Inflammatory/infectious cutaneous side effects of biological drugs in patients with psoriasis: a general review with personal data.
    Rongioletti F; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2014 Jun; 149(3):311-6. PubMed ID: 24819758
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
    Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
    Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Puig L
    G Ital Dermatol Venereol; 2017 Feb; 152(1):28-35. PubMed ID: 27627100
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
    Sánchez-Regaña M; Dilmé E; Puig L; Bordas X; Carrascosa JM; Ferran M; Herranz P; García-Bustinduy M; López Estebaranz JL; Alsina M; Rodríguez MA; Ribera M; Fernández-López E; Moreno JC; Belinchón Romero I; Vidal D;
    Actas Dermosifiliogr; 2010 Mar; 101(2):156-63. PubMed ID: 20223158
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biologics in pediatric psoriasis - efficacy and safety.
    Dogra S; Mahajan R
    Expert Opin Drug Saf; 2018 Jan; 17(1):9-16. PubMed ID: 29022425
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
    Borren NZ; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.